Doorgaan naar hoofdnavigatie
Doorgaan naar zoeken
Ga verder naar hoofdinhoud
Prinses Máxima Centrum Voorpagina
Nederlands
English
Content zoeken bij Prinses Máxima Centrum
Voorpagina
Profielen
Onderzoeksgroepen
Uitrusting
Onderzoeksoutput
Prijzen
Activiteiten
Knipsels
Organoid Models of Human Liver Cancers Derived from Tumor Needle Biopsies
Sandro Nuciforo
, Isabel Fofana
, Matthias S Matter
, Tanja Blumer
, Diego Calabrese
, Tujana Boldanova
, Salvatore Piscuoglio
, Stefan Wieland
,
Femke Ringnalda
, Gerald Schwank
, Luigi M Terracciano
, Charlotte K Y Ng
, Markus H Heim
Onderzoeksoutput
:
Bijdrage aan tijdschrift
›
Artikel
›
Onderzoek
›
peer review
Overzicht
Vingerafdruk
Vingerafdruk
Duik in de onderzoeksthema's van 'Organoid Models of Human Liver Cancers Derived from Tumor Needle Biopsies'. Samen vormen ze een unieke vingerafdruk.
Sorteer per
Gewicht
Alfabetische volgorde
Keyphrases
Advanced Hepatocellular Carcinoma
33%
Adverse Drug
33%
Adverse Effects
33%
Cancer Causes
33%
Cancer Mortality
33%
Core Needle Biopsy
100%
Drug Resistance
33%
Etiology
33%
Expression Pattern
33%
Genetic Heterogeneity
33%
Hepatocellular Carcinoma
100%
Hepatocellular Carcinoma Patient
33%
Human Liver Cancer
100%
In Vitro Model
33%
Liver Cancer
33%
Liver Cancer Organoids
33%
Multikinase Inhibitor
33%
Organoid Culture
33%
Organoid Models
100%
Organoids
33%
Primary Liver Cancer
33%
Proof of Concept Study
33%
Sorafenib
66%
Tailored Therapy
33%
Test Sensitivity
33%
Treatment Options
33%
Tumor
100%
Tumor Heterogeneity
33%
Tumor Marker
33%
Tumor Stage
33%
Medicine and Dentistry
Adverse Effect
20%
Cancer Staging
20%
Drug Resistance
20%
Etiology
20%
Genetic Heterogeneity
20%
Hepatocellular Carcinoma
100%
In Vitro
20%
Liver Cancer
100%
Malignant Neoplasm
20%
Needle Biopsy
100%
Neoplasm
100%
Organoid
100%
Sorafenib
40%
Treatment Option
20%
Tumor
20%
Tumor Marker
20%
Tumour Heterogeneity
20%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Effect
20%
Cancer Staging
20%
Drug Resistance
20%
Etiology
20%
Liver Cancer
100%
Liver Cell Carcinoma
100%
Malignant Neoplasm
20%
Neoplasm
100%
Sorafenib
40%
Tumor Marker
20%